Literature DB >> 10647609

FDG PET measurement of the proliferative potential of non-small cell lung cancer.

K Higashi1, Y Ueda, M Yagishita, Y Arisaka, A Sakurai, M Oguchi, H Seki, Y Nambu, H Tonami, I Yamamoto.   

Abstract

UNLABELLED: The goals of this study were to correlate FDG uptake with cell proliferation and cellular density in non-small cell lung cancer.
METHODS: Thirty-one patients with 32 non-small cell lung cancers were examined with FDG PET. For semiquantitative analysis, standardized uptake values (SUVs) were calculated. All patients underwent thoracotomy within 4 wk after the FDG PET study. Cell proliferation was immunohistochemically assessed as the relative number of cells expressing the proliferating cell nuclear antigen ([PCNA] labeling index). Cellular density was also evaluated using light microscopy.
RESULTS: SUVs correlated significantly with PCNA labeling index (r = 0.740; P < 0.0001) but only weakly with cellular density (r = 0.392; P = 0.0266). High FDG uptake correlated with high PCNA expression. The PCNA labeling index and SUVs were significantly lower in bronchioloalveolar carcinomas (n = 8) (12.3 +/- 9.45% and 1.45 +/- 0.76, respectively) than in nonbronchioloalveolar carcinomas (n = 19) (33.5 +/- 21.8%, P = 0.015, and 3.75 +/- 1.93, P = 0.003, respectively). However, no significant differences in cellular density were seen between bronchioloalveolar carcinomas and nonbronchioloalveolar carcinomas.
CONCLUSION: FDG uptake is related to cell proliferation rather than to the cellular density of non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647609

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

1.  FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Christos Colovos; Kei Suzuki; Nabil P Rizk; Mark P S Dunphy; Emily C Zabor; Camelia S Sima; Akihiko Yoshizawa; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

2.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

3.  Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT.

Authors:  Jing Gu; Pek-Lan Khong; Silun Wang; Queenie Chan; Wailun Law; Jingbo Zhang
Journal:  Mol Imaging Biol       Date:  2010-09-25       Impact factor: 3.488

4.  Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease.

Authors:  Chae Hong Lim; Seung Hyup Hyun; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

5.  Case report: Positron emission tomography fails to detect pulmonary adenocarcinoma recurrence after radiofrequency ablation.

Authors:  Cara Odenthal; Karin Steinke
Journal:  J Radiol Case Rep       Date:  2013-11-01

6.  Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

Authors:  S M Eschmann; G Friedel; F Paulsen; M Reimold; T Hehr; W Budach; J Scheiderbauer; H J Machulla; H Dittmann; R Vonthein; R Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-04       Impact factor: 9.236

7.  Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.

Authors:  L Heijmen; C J A Punt; E G W Ter Voert; L F de Geus-Oei; A Heerschap; J Bussink; C G J Sweep; V Zerbi; W J G Oyen; P N Span; O Boerman; H W M van Laarhoven
Journal:  Invest New Drugs       Date:  2013-01-17       Impact factor: 3.850

8.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

9.  11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.

Authors:  Kotaro Higashi; Yoshimichi Ueda; Ichiro Matsunari; Yuko Kodama; Ryosuke Ikeda; Katsuyuki Miura; Suzuka Taki; Takahiro Higuchi; Hisao Tonami; Itaru Yamamoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

10.  Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma.

Authors:  Motoyasu Sagawa; Kotaro Higashi; Makoto Sugita; Yoshimichi Ueda; Sumiko Maeda; Hirohisa Toga; Tsutomu Sakuma
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.